Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.
Three approved antibody-drug conjugates now offer new combination strategies and hope for women with hard-to-treat gynecologic cancers.
This Nature Reviews Clinical Oncology review from major cancer centers comprehensively covers the current landscape of three approved ADCs in gynaecological cancers, highlighting combination strategies with checkpoint inhibitors and resistance mechanisms as top priorities. The review frames the rapidly evolving ADC field and provides a roadmap for treatment sequencing in an area of high unmet need.
What the study was
- Study design
- Narrative review
- Population
- Patients with gynaecological malignancies (ovarian, cervical, endometrial)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nat Rev Clin Oncol
Why it surfaced
Authoritative Nat Rev Clin Oncol review of ADC landscape in gynaecological cancers from leading US cancer centers. Covers all three approved agents and future directions. High signal for pipeline tracking.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.